New hope for head and neck cancer patients who Can't take chemo
NCT ID NCT07445048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new treatment for people with high-risk head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. Participants receive radiation therapy combined with two drugs (nimotuzumab and benmelstobart) to see if this approach improves disease-free survival compared to standard care. The study enrolls 370 adults and follows them for up to 3 years after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai 9th people's hospital
RECRUITINGShanghai, 200011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?